The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after identifying a safety concern.

Novavax (NASDAQ:NVAX) shares climbed 12% premarket on Monday after the U.S. FDA lifted clinical hold on the investigational new drug application for the pharma firm’s COVID-19-Influenza ...

The Food and Drug Administration halted Novavax's trial of a combination vaccine for COVID and influenza, as well as a standalone flu shot, after a participant suffered a serious adverse event ...

The FDA has put Novavax's trial of an experimental COVID-flu vaccine combination on hold after one person who received the shot reported nerve damage, the company said Wednesday.

FDA places a clinical hold on Novavax's COVID-19-influenza vaccine trials due to a serious adverse event in a Phase 2 participant. Novavax's COVID-19 IND and European approval for its updated ...

Novavax shares plummet 30% as FDA places clinical hold on COVID-19 and influenza combination vaccine due to serious adverse event.

That deal saw Novavax retain the rights to its combo COVID-flu vaccine, while Sanofi has the sole license to use Novavax’s adjuvanted COVID-19 vaccine in combination with Sanofi's own flu ...

US News: The US Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines af.

The U.S. Food and Drug Administration has put on hold a trial of Novavax's COVID-influenza and its standalone flu vaccines after a participant who took the combination shot reported nerve damage ...

Novavax (NVAX) shares surge 12% as FDA lifts clinical hold on COVID-19-Influenza Combination vaccine candidates.

Sanofi said the clinical hold has "nothing to do with" its partnership with Novavax. Outside of the agreement, the companies can individually develop their own flu-COVID vaccines and other ...